Loading...
•
Sep 30, 2021
Schrodinger Q3 2021 Earnings Report
Reported a 16% increase in total revenue year-over-year, driven by growth in both software and drug discovery segments and continued to invest in R&D to advance its technology and drug discovery pipeline.
Key Takeaways
Schrödinger reported a total revenue of $29.9 million for Q3 2021, a 16% increase compared to Q3 2020. Software revenue was $24.3 million, and drug discovery revenue was $5.6 million. The company's net loss was $35.0 million, driven by adjustments to the fair value of the company’s equity investments as well as planned investments to advance the company’s growth strategy.
Total revenue was $29.9 million, up 16% year-over-year.
Software revenue was $24.3 million.
Drug discovery revenue was $5.6 million, including $4.4 million from the collaboration with Bristol Myers Squibb.
Net loss was $35.0 million.
Revenue by Segment
Forward Guidance
Schrödinger expects total revenue to range from $124 million to $134 million for the fiscal year ending December 31, 2021. The company is maintaining its full-year software revenue expectation of $102 million to $110 million. The company is adjusting its full-year drug discovery revenue expectation to a range of $22 million to $24 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...